Quantitative muscle ultrasound as a disease biomarker in hereditary transthyretin amyloidosis with polyneuropathy
Neurological Sciences · 2024
DOI: 10.1007/s10072-024-07340-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurological Sciences, 2024. Verfasst von Siew Yin Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Ultrasonography, Muscle, Skeletal, Polyneuropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: There is an increasing need for a reproducible and sensitive outcome measure in patients with hereditary transthyretin amyloidosis (ATTRv) with polyneuropathy (PN) due to the emergence of disease modifying therapies. In the current study, we aimed to investigate the role of quantitative muscle ultrasound (QMUS) as a disease biomarker in ATTRv-PN. METHODS: Twenty genetically confirmed ATTRv amyloidosis patients (nine symptomatic, 11 pre-symptomatic) were enrolled prospectively between January to March 2023. Muscle ultrasound was performed on six muscles at standardized locations. QMUS parameters included muscle thickness (MT) and muscle echo intensity (EI). Twenty-five age- and sex-matched healthy controls were recruited for comparison. Significant QMUS parameters were correlated with clinical outcome measures. RESULTS: Muscle volume of first dorsal interosseus (FDI) muscle [measured as cross-sectional area (CSA)] was significantly lower in symptomatic patients compared to healthy controls and pre-symptomatic carriers (98.3 ± 58.0 vs. 184.4 ± 42.5 vs. 198.3 ± 56.8, p < 0.001). EI of biceps and FDI for symptomatic ATTRv-PN patients were significantly higher compared to the other two groups (biceps: 76.4 ± 10.8 vs. 63.2 ± 11.5 vs. 59.2 ± 9.0, p = 0.002; FDI: 48.2 ± 7.5 vs. 38.8 ± 7.5 vs. 33.0 ± 5.3, p < 0.001). CSA of FDI and EI of biceps and FDI correlated with previous validated outcome measures [polyneuropathy disability score, neuropathy impairment score, Karnofsky performance scale, Rasch-built overall disability scale, European quality of life (QoL)-5 dimensions and Norfolk QoL questionnaire-diabetic neuropathy]. CONCLUSION: QMUS revealed significant difference between ATTRv amyloidosis patients and healthy controls and showed strong correlation with clinical outcome measures. QMUS serves as a sensitive and reliable biomarker of disease severity in ATTRv-PN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia.
- Department of Medicine, Neurology Unit, University of Malaya, Kuala Lumpur, Malaysia. cytan@ummc.edu.my.
- Department of Medicine, Faculty of Medicine, Universiti Malaya, Lembah Pantai, 50603, Kuala Lumpur, Malaysia. cytan@ummc.edu.my.
- Neurophysiology Laboratory, University of Malaya Medical Centre, Kuala Lumpur, Malaysia.
Zitieren
APA
Tan, S. Y., Tan, C. Y., Yahya, M. A., Low, S. C., Shahrizaila, N., & Goh, K. J. (2024). Quantitative muscle ultrasound as a disease biomarker in hereditary transthyretin amyloidosis with polyneuropathy. Neurological Sciences. https://doi.org/10.1007/s10072-024-07340-y
Vancouver
Tan SY, Tan CY, Yahya MA, Low SC, Shahrizaila N, Goh KJ. Quantitative muscle ultrasound as a disease biomarker in hereditary transthyretin amyloidosis with polyneuropathy. Neurological Sciences. 2024. doi:10.1007/s10072-024-07340-y
BibTeX
@article{Tan2024,
author = {Tan, Siew Yin and Tan, Cheng Yin and Yahya, Mohd Azly and Low, Soon Chai and Shahrizaila, Nortina and Goh, Khean Jin},
title = {Quantitative muscle ultrasound as a disease biomarker in hereditary transthyretin amyloidosis with polyneuropathy},
journal = {Neurological Sciences},
year = {2024},
doi = {10.1007/s10072-024-07340-y}
}
EUVIMED